A revolutionary therapy to lower bad cholesterol, Leqvio (Inclisiran), has been approved by the US Food and Drug Administration (FDA) as well as the European Commission (EC). Leqvio is the first and only approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction.

In studies, Leqvio showed LDL-C reduction of up to 52% when compared to placebo. Patients in the study had a history of cardiovascular disease and were also taking a high-dose statin (such as Crestor or Lipitor).

Leqvio is different from other therapies on the market because of its unique dosing schedule. Leqvio only requires two maintenance doses a year, done by a healthcare provider. This eliminates the need to self-inject and reduces the incidence of forgetting to take a dose. Making it easier for patients to manage their cholesterol.

While data for Leqvio shows effectiveness in lowering cholesterol levels, scientists have reason to believe that lowering cholesterol levels, would hopefully lower the incidence of heart attack and stroke as well. To prove this, long-term clinical trials will begin to observe patients on Leqvio.

Rochester Clinical Research is proud to begin a clinical trial through our community research division to observe if Leqvio, when taken in addition to a statin, will lower the incidence of heart attack, stroke, and cerebral vascular death in patients with high cholesterol and a history of cardiovascular disease.

RCR is seeking volunteers over the age of 40, with high cholesterol, currently taking Lipitor or Crestor, with a history of ANY of the following: Myocardial Infarction, Stroke or symptoms of peripheral artery disease for this study.

If you qualify for this study you may receive investigational treatment as well as study-related care, and compensation for your time and travel.

Interested in learning more? Click here to see if you or a loved one may qualify for this study.